Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 81 to 90 of 242 total matches.
Antiviral Drugs for COVID-19 in Vaccinated Outpatients
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
COVID-19 and mortality in high risk patients. Clin
Infect Dis 2023; 76:e342.
4. NR Aggarwal et al ...
Three products are currently available in the US for
treatment of high-risk,1 nonhospitalized adults with
mild to moderate COVID-19: oral ritonavir-boosted
nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and
oral molnupiravir (Lagevrio). Remdesivir is FDA-approved
for such use; nirmatrelvir/ritonavir and
molnupiravir are available under an FDA Emergency
Use Authorization. Because the pivotal clinical trials
of these products for outpatient use were conducted
in patients who were not vaccinated against
COVID-19, some clinicians have questioned whether
they can benefit vaccinated...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):33-4 doi:10.58347/tml.2023.1671a | Show Introduction Hide Introduction
Ritlecitinib (Litfulo) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
warning about an increased risk of serious infections, malignancies (particularly lymphomas), major ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an
oral JAK and TEC kinase family inhibitor, for treatment
of severe alopecia areata in patients ≥12 years old.
Ritlecitinib is the second oral drug to be approved
in the US for treatment of severe alopecia areata;
baricitinib (Olumiant), a JAK inhibitor, is approved
only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6 doi:10.58347/tml.2023.1690a | Show Introduction Hide Introduction
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
and clarithromycin (Voquezna
Triple Pak) for treatment of Helicobacter pylori
infection in adults.1
GERD ...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):203-5 doi:10.58347/tml.2023.1692b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
: Infections, injection-site reactions, arthralgia,
rash, and headache are most common. Anaphylaxis ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
-site reactions, and rash.
It can also increase the risk of infection. Serious
hypersensitivity ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4 doi:10.58347/tml.2024.1715d | Show Introduction Hide Introduction
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
% of RVVC infections and are less
susceptible to standard treatment. Resistance to azole
antifungals ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
were upper respiratory tract
infection, blood creatine phosphokinase increases, acne,
neutropenia ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
living compared to addition of placebo.
Adverse Effects: Headache is the most common. Infections ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
An EUA for Baricitinib (Olumiant) for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
sheet) in
1033 hospitalized adults with confirmed SARS-CoV-2
infection and either radiographic ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be used
in combination with the IV antiviral drug remdesivir
(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in...
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
― A skin infection
caused by a poxvirus, molluscum contagiosum is
most common in preschool ...
The FDA has approved cantharidin 0.7% solution
(Ycanth – Verrica) for topical treatment of molluscum
contagiosum in patients ≥2 years old. Ycanth
was the first drug to be approved in the US for this
indication. A 10.3% gel formulation of berdazimer
(Zelsuvmi), a nitric oxide-releasing agent, has
also been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9 doi:10.58347/tml.2024.1696b | Show Introduction Hide Introduction